Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children

NCT01893554 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

88

Enrollment

NIH

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: RSV ΔNS2 Δ1313 I1314L Vaccine
BIOLOGICAL: Placebo

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]